product name Orlistat
Description: Orlistat (also known as tetrahydrolipstatin, or Ro 18-0647, Lipase Inhibitor, THL ) is a general lipase inhibitor with IC50 of 122 ng/ml for PL from human duodenal juice. Orlistat is a drug designed to treat obesity. Orlistat is the saturated derivative of lipstatin, a potent natural inhibitor of pancreatic lipases isolated from the bacterium Streptomyces toxytricini. Mechanistic studies suggest that Orlistat inhibits the thioesterase domain of fatty acid synthase (FAS) and as a result halts cell proliferation and causes cell apoptosis. More detailed experiments show that gradually Orlistat affects the retinoblastoma protein pathway and leads to cell-cycle arrest at G1/S boundary.
References: J. Biol. Chem. 279: 30540-30545, 2004; Cancer Res. 64: 2070-2075, 2004.
495.73
Formula
C29H53NO5
CAS No.
96829-58-2
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 99 mg/mL (199.7 mM)
Water: <1 mg/mL
Ethanol: 99 mg/mL (199.7 mM)
Solubility (In vivo)
Synonyms
Ro 18-0647
other peoduct :
| In Vitro |
In vitro activity: Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | |
| Animal model | |
| Formulation & Dosage | |
| References |
